Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

• Status: Recruiting
• Trial end date: 2031-12-14
• Target enrollment: 0
• Participant gender: All

Summary

This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yang Li
• Collaborator: Ruijin Hospital
• Treatments: Arsenic Trioxide

Criteria

Inclusion Criteria:

1. Pathological diagnosis basis of malignant tumor；

2. Patients not more than 18 years old;

3. Patient has either germline or somatic p53 mutations, which was shown to be partially/completely restored to function by ATO in in vitro experiments (http://www.rescuep53.net);

4. There are measurable lesions;

5. Guardians agreed and signed informed consent.

Exclusion Criteria:

Patients with one or more critical organs failure such as heart, brain, kidney failure.